Miniaturized GPCR signaling studies in 1536-well format.

Area of Science:

• Pharmacology
• Biochemistry
• Drug Discovery

Background:

• G protein-coupled receptors (GPCRs) regulate vital physiological processes and are key targets for novel drug development.
• Accurate and efficient assays are crucial for accelerating the discovery of drug candidates that modulate GPCR activity.

Purpose of the Study:

• To optimize and validate the Promega cAMP-Glo Assay in a 1536-well format for high-throughput screening (HTS) of GPCR-targeted compounds.
• To assess the assay's robustness and applicability in primary and secondary screening for drug discovery.

Main Methods:

• Homogenous bioluminescent assay using Promega cAMP-Glo technology.
• Integration with Labcyte Echo 555 acoustic liquid handler and Deerac Fluidics Equator HTS reagent dispenser for miniaturized screening.
• Optimization and validation of the assay in 1536-well plates for GPCR compound screening.

Main Results:

• Successful optimization and validation of the cAMP-Glo assay in a 1536-well format.
• Demonstrated utility in primary screening of known GPCR agonists and antagonists.
• Confirmed primary screening hits through robust secondary screening assays.

Conclusions:

• The optimized, miniaturized GPCR assay enables effective and efficient screening of potential drug candidates.
• This high-throughput approach accelerates the identification of novel therapeutics targeting GPCRs.
• The validated assay provides a robust platform for drug discovery initiatives focused on GPCR modulation.